Collatamp(TM) EG Receives Marketing Authorization in Brazil

CHARLOTTE, NC -- (MARKET WIRE) -- 04/07/08 -- BurnsAdler Pharmaceuticals, Inc. ("BurnsAdler") announced today that Collatamp(TM) EG has received marketing approval from ANVISA -National Agency for Surveillance in Brazil. Collatamp(TM) EG is a fully resorbable Gentamicin-impregnated Collagen Sponge, used as a surgical implant for local haemostasis of capillary, parenchymatous and seeping hemorrhages in areas with a high risk of infection. BurnsAdler will be co-marketing Collatamp(TM) EG with its local partner Meizler Biopharma, S.A. ("Meizler").

Bryan Somerville, Chief Operating Officer of BurnsAdler, remarked, "We are very pleased to receive approval for Collatamp(TM) EG in Brazil and for the opportunity to bring this advanced technology into a new market. Collatamp(TM) EG is the only Gentamycin-impregnated Collagen Sponge in the world, and allows medical providers to reduce patient costs and mean duration of hospital stay. Through our strategic partnership with Meizler and direct promotional efforts, we look forward to positive results in Brazil."

Avi Meizler, President of Meizler, remarked, "It is a great pleasure to share with you the approval and very soon launching of Collatamp(TM) in Brazil. We are truly confident that this very valuable product -- within the Brazilian market -- will definitely contribute in the improvement of the medical practices and, of course, better quality of life for the patients. We are also looking forward to sharing with our partners, BurnsAdler Pharmaceuticals, the success of Collatamp(TM) in the very near future."

About Collatamp(TM) EG

Collatamp(TM) EG is based on Innocoll Inc.'s proprietary collagen CollaRx(R) (collagen sponge matrix) drug delivery technology. It is approved in over 50 countries worldwide and is marketed under a variety of other trade names in Europe, the Middle East, Africa and Asia. BurnsAdler licensed the product for sale in various Latin American countries from Innocoll Pharmaceuticals in August 2006. In 2007, EUSA Pharma Inc. acquired all worldwide rights from Innocoll, with the exception of the U.S., and all agreements with BurnsAdler were maintained.

About Meizler Biopharma, S.A.

Meizler is a Brazilian medical and hospital-focused company that has been in existence for eighteen years. The company has held several international partnerships with a variety of companies in Europe, the United States and Asia. Meizler's portfolio currently includes products in the following categories: anesthetic, antipsychotic, antibiotics, biotechnology-vaccines, cardiovascular, haemoderivaties and human reproduction hormones. www.meizler.com.br

About BurnsAdler Pharmaceuticals, Inc.

BurnsAdler is a specialty pharmaceutical company that in-licenses and promotes products in South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler's portfolio currently includes products targeted for the gastroenterology, cardiovascular, orthopedic, oncology, and critical care markets.

For additional information about this news release contact Natalie Legra at +1.704.552.8410 Ext. 232. For additional information about BurnsAdler, please refer to the company's website at www.burnsadler.com.

BurnsAdler Contact: Natalie Legra Marketing Associate +1.704.552.8410 (phone) Ext. 232 +1.704.552.8411 (fax) nlegra@burnsadler.com

2008-04-07 18:20:13 0330094 MARKETWIRE